Brii Biosciences BRIBF Stock
Brii Biosciences Price Chart
Brii Biosciences BRIBF Financial and Trading Overview
| Brii Biosciences stock price | 0.16 USD |
| Previous Close | 0.16 USD |
| Open | 0.25 USD |
| Bid | 0.12 USD x 500000 |
| Ask | 0.17 USD x 500000 |
| Day's Range | 0.23 - 0.25 USD |
| 52 Week Range | 0.16 - 0.26 USD |
| Volume | 4.15K USD |
| Avg. Volume | 79 USD |
| Market Cap | 166.74M USD |
| Beta (5Y Monthly) | 1.259 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.05 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
BRIBF Valuation Measures
| Enterprise Value | -1870825088 USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.6904507 |
| Price/Book (mrq) | 0.47692907 |
| Enterprise Value/Revenue | -52.628 |
| Enterprise Value/EBITDA | 6.538 |
Trading Information
Brii Biosciences Stock Price History
| Beta (5Y Monthly) | 1.259 |
| 52-Week Change | -40.23% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 0.26 USD |
| 52 Week Low | 0.16 USD |
| 50-Day Moving Average | 0.18 USD |
| 200-Day Moving Average | 0.21 USD |
BRIBF Share Statistics
| Avg. Volume (3 month) | 79 USD |
| Avg. Daily Volume (10-Days) | 555 USD |
| Shares Outstanding | 721.18M |
| Float | 594.68M |
| Short Ratio | N/A |
| % Held by Insiders | 5.01% |
| % Held by Institutions | 17.75% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -325.70% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -7.076% |
| Return on Equity (ttm) | -9.090% |
Income Statement
| Revenue (ttm) | 35.55M USD |
| Revenue Per Share (ttm) | 0.05 USD |
| Quarterly Revenue Growth (yoy) | 24.39% |
| Gross Profit (ttm) | 35.55M USD |
| EBITDA | -286136992 USD |
| Net Income Avi to Common (ttm) | -222624000 USD |
| Diluted EPS (ttm) | -0.05 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.94B USD |
| Total Cash Per Share (mrq) | 2.69 USD |
| Total Debt (mrq) | 8.93M USD |
| Total Debt/Equity (mrq) | 0.38 USD |
| Current Ratio (mrq) | 60.734 |
| Book Value Per Share (mrq) | 0.4847681 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -338808000 USD |
| Levered Free Cash Flow (ttm) | -269470240 USD |
Profile of Brii Biosciences
| Country | United States |
| State | N/A |
| City | Beijing |
| Address | Building 7, International Science Park |
| ZIP | 100192 |
| Phone | N/A |
| Website | https://www.briibio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 75 |
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in c for the treatment of HIV. It also develops Soralimixinfor the treatment of multi-drug resistant or extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with treatment-refractory mycobacterium avium complex (MAC) lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
Q&A For Brii Biosciences Stock
What is a current BRIBF stock price?
Brii Biosciences BRIBF stock price today per share is 0.16 USD.
How to purchase Brii Biosciences stock?
You can buy BRIBF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Brii Biosciences?
The stock symbol or ticker of Brii Biosciences is BRIBF.
Which industry does the Brii Biosciences company belong to?
The Brii Biosciences industry is Biotechnology.
How many shares does Brii Biosciences have in circulation?
The max supply of Brii Biosciences shares is 721.18M.
What is Brii Biosciences Price to Earnings Ratio (PE Ratio)?
Brii Biosciences PE Ratio is now.
What was Brii Biosciences earnings per share over the trailing 12 months (TTM)?
Brii Biosciences EPS is -0.05 USD over the trailing 12 months.
Which sector does the Brii Biosciences company belong to?
The Brii Biosciences sector is Healthcare.